Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
- Once an individual becomes eligible, they remain eligible until their 80th birthday
- Adults who are severely immuncompromised aged 50 or over are eligible with no upper age limit
- SHINGRIX is given as a 2 dose schedule. The national guidance for administration of the second dose as part of the national immunisation programme differs from the SHINGRIX SPC
The Shingles National Immunisation Programme: How can you help to protect your eligible patients?
Are you aware of the changes to the Shingles National Immunisation Programme?1
Are you effectively implementing the Shingles National Immunisation Programme? View our implementation hub
Shingles is a painful disease that can have serious and long-lasting complications2
Prescribing information (GB & NI)
Summary of product characteristics (GB)
Summary of product characteristics (NI)
References
- DH Green Book: Ch28a Shingles (Mar 2024)
- UK NICE Clinical Knowledge Summaries, 2024. Shingles: What are the complications?
- SHINGRIX. Summary of Product Characteristics (Great Britain)
- SHINGRIX. Summary of Product Characteristics (Northern Ireland)
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App Store. Adverse events should also be reported to GSK on 0800 221 441 or UKSafety@gsk.com.
SHINGRIX is owned by or licensed to the GSK group of companies.
© 2024 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.
December 2024 | PM-GB-SGX-WCNT-230004 (V5.0)
